Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
The combination of Cisplatin with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death[1].Lexatumumab (0-10 µg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines[2].
Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with Dacarbazine [2].
References:
[1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66.
[2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492.